Checking blood test results in advanced lung cancer after treatment
Part of Cancer, Lungs & breathing clinical trials.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer confirmed by a biopsy or fluid test.
- You are 18 to 75 years old.
- You are newly diagnosed and have not received cancer treatment yet (treatment-naive).
- Your cancer tests show no “driver gene” changes (driver gene negative).
- Your cancer is stage IIIB-C and your doctors think it may be surgically removed after initial treatment.
- Your general health score is 0 to 1 (you are up and about most of the time).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study is for people with advanced non-small cell lung cancer whose tumors do not have certain genetic changes (called driver mutations) and whose first treatment did not work well or caused bad side effects within 6 months. The researchers want to use a special test (DNA/RNA-NGS) to look for hidden genetic alterations that might explain why the cancer didn't respond.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.